Lupin enters into non-exclusive patent license agreement with Takeda

18 Sep 2024 Evaluate

Lupin has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company (Takeda), to commercialize Vonoprazan Tablets in the Indian market. The drug will be marketed under the brand name Lupin’s Lupivon and will be available in two strengths - 10 mg and 20 mg. Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2112.00 -43.25 (-2.01%)
15-Jan-2025 09:41 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1756.15
Dr. Reddys Lab 1323.90
Cipla 1433.50
Lupin 2112.00
Zydus Lifesciences 985.00
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.